Department of Otolaryngology - Head and Neck Surgery, Mayo Clinic, Rochester, MN 55905, USA.
Department of Laboratory Medicine & Pathology, Mayo Clinic, Rochester, MN 55905, USA.
Am J Otolaryngol. 2022 Jan-Feb;43(1):103194. doi: 10.1016/j.amjoto.2021.103194. Epub 2021 Sep 2.
Determine rates of intra-parotid and neck nodal metastasis, identify risk factors for recurrence, and report outcomes in patients with primary high-grade parotid malignancy who undergo total parotidectomy and neck dissection.
MATERIALS & METHODS: Retrospective review of patients undergoing total parotidectomy and neck dissection for high-grade parotid malignancy between 2005 and 2015. The presence and number of parotid lymph nodes, superficial and deep, as well as cervical lymph nodes involved with metastatic disease were assessed. Risk factors associated with metastatic spread to the parotid deep lobe were identified and recurrence rates reported.
75 patients with median follow-up time of 47 months. 35 patients (46.7%) had parotid lymph node metastasis. Seven patients (9.3%) had deep lobe nodal metastasis without metastasis to the superficial lobe nodes. Nine patients (12%) had positive intra-parotid nodes without positive cervical nodes. Cervical nodal disease was identified in 49.3% patients (37/75). Local, parotid-bed recurrence rate was 5.3% (4/75). Regional lymph node recurrence rate was also 5.3% (4/75). Rate of distant metastasis was 30.6% (23/75). The overall disease free survival rate for all patients at 2 and 5 years were 71% and 60% respectively.
Parotid lymph node metastasis occurred at a similar rate to cervical lymph node metastasis (46.7% and 49.3%, respectively). Deep lobe parotid nodal metastasis occurred in nearly a quarter of patients and can occur without superficial parotid nodal metastasis. Rate of recurrence in the parotid bed, which may represent local or regional recurrence, was similar to regional cervical lymph node recurrence. Total parotidectomy and neck dissection should be considered high-grade parotid malignancy regardless of clinical nodal status.
确定腮腺内和颈部淋巴结转移的发生率,确定复发的危险因素,并报告接受腮腺全切除术和颈部解剖术的原发性高级别腮腺恶性肿瘤患者的治疗结果。
回顾性分析 2005 年至 2015 年间行腮腺全切除术和颈部解剖术治疗高级别腮腺恶性肿瘤的患者。评估腮腺内的浅部和深部淋巴结以及颈部淋巴结中是否存在转移病灶及其数量。确定与腮腺深叶转移相关的危险因素,并报告复发率。
75 例患者的中位随访时间为 47 个月。35 例(46.7%)患者发生腮腺淋巴结转移。7 例(9.3%)患者存在深部淋巴结转移,但无浅部淋巴结转移。9 例(12%)患者存在腮腺内淋巴结阳性但颈部淋巴结无转移。49.3%(37/75)的患者存在颈部淋巴结疾病。局部和腮腺床复发率为 5.3%(4/75)。区域淋巴结复发率也为 5.3%(4/75)。远处转移率为 30.6%(23/75)。所有患者的 2 年和 5 年无病生存率分别为 71%和 60%。
腮腺淋巴结转移的发生率与颈部淋巴结转移相似(分别为 46.7%和 49.3%)。近四分之一的患者发生腮腺深部淋巴结转移,且可无腮腺浅部淋巴结转移。腮腺床复发率(可能代表局部或区域复发)与颈部区域淋巴结复发率相似。无论临床淋巴结状态如何,腮腺全切除术和颈部解剖术均应考虑用于高级别腮腺恶性肿瘤。